| Today’s Big NewsAug 10, 2023 |
| By Fraiser Kansteiner Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act. |
|
|
|
| Philadelphia, PA |  |
|
|
By Nick Paul Taylor Novo Nordisk is keeping its foot on the gas as it strives to carve out a strong position in the exploding obesity market, inking a deal worth up to $1.1 billion to buy a biotech that is dusting off an old approach to triggering weight loss. |
By Andrea Park Though Rockley Photonics got off to a rocky start this year by filing for Chapter 11 bankruptcy in January, the proceedings ultimately lasted less than six months from start to finish—and the company is already back to work on the development of its wearable biosensors. |
By Angus Liu Johnson & Johnson is digging its multiple myeloma moat deeper. The FDA has signed off on the company's Talvey, a first-in-class bispecific antibody targeting GPRC5D. |
|
Thursday, August 3, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
By Annalee Armstrong And just like that, we have a crowded race to be the first approved NASH treatment—a market that could grow to $108.4 billion globally by 2030. |
By Conor Hale A startup that aims to integrate robotics with minimally invasive heart valve procedures has collected $31.4 million in venture capital funding. |
By Kevin Dunleavy As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its staying power compared to that of Roche’s upstart Vabysmos—which has taken the macular degeneration (AMD) market by storm since receiving approval 19 months ago. |
By Max Bayer Some six months removed from laying off a quarter of its staff, Surrozen has once again found itself in cash preservation mode, culling two research programs to save money. |
By Andrea Park Not to be outdone by the FDA, regulators in Europe have given the all-clear to a new indication for Theranica’s neuromodulation armband for migraine treatment. |
By Zoey Becker The company will pay a fine of $158,208 after reaching an agreement with the U.S. Environmental Protection Agency. The agency discovered the violations after a 2021 inspection of Genentech's facility in South San Francisco. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss how to support patients during the cancer drug shortage, plus this week's headlines. |
|
|---|
|
|
|
Wednesday, August 30, 2023 | 1pm ET/ 10am PT Enzymes have long demonstrated their utility as a green alternative to metal-based catalysts, but the evolution time required can be significant. Join this webinar to learn about an extracellular strategy that reduces the evolution cycle and enables biocatalysis to be used much earlier in development. Register now. 
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
